A clinical trial begins with an application, and the length of that application sets the pace of everything after it. The UK has replaced a regulatory process it had used for two decades. The question is whether the replacement changes how quickly trials start, and the evidence for that is a target rather than a result.
The regulations and their dates
The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 amend the Medicines for Human Use (Clinical Trials) Regulations 2004. The core instrument is secondary legislation, which means the framework's substance sits in statutory instruments rather than in a new Act.
The regulations were first laid before Parliament in December 2024 and signed into law on 11 April 2025, when a 12-month rollout began. The MHRA stated that they would take full effect from 10 April 2026.
That date did not hold. In a post-publication note, the MHRA recorded that the regulations would come into force on 28 April 2026 instead, as the statutory instrument needed to be re-signed on 28 April 2025 following a technical issue during final processing on the digital legislation platform.
The delay is worth stating plainly because it illustrates what implementation risk looks like in practice. Nothing in the policy changed. The instrument was re-signed and the commencement date moved by eighteen days.
The regulations were developed by the MHRA in partnership with the Health Research Authority, and the HRA states that they reflect feedback from patients, researchers, healthcare professionals and industry. That is a description of how the text was assembled, and it is not independent evidence about how it performs. The distinction matters for anyone reading the framework's stated aims as findings.
The HRA separately describes them as the most significant overhaul of UK clinical trial regulations in 20 years. That is a statement about the period since the previous framework took effect, not a claim about the magnitude of the effect on approval times.
What the framework changes
Two mechanisms are written into law. Combined Review is a process that lets a sponsor apply for research ethics opinion and regulatory approval together instead of separately. The notification scheme covers the initial applications and amendments for some lower-risk trials, replacing full authorisation with a lighter route.
The mechanics of Combined Review are more specific than the summary suggests. A research team makes a single application through one part of the Integrated Research Application System, which reaches the MHRA and a Research Ethics Committee at the same time. The two reviews run in parallel, any requests for further information are raised jointly, and a single response produces a single decision from both. Study-wide review, such as Health Research Authority approval, is normally issued alongside them.
The MHRA describes the intended effect as reducing duplication and cutting unnecessary delays while maintaining oversight, and as reducing bureaucracy for lower-risk trials. The Health Research Authority's Director of Approvals Service described embedding Combined Review in law as strengthening the focus on transparency and proportionality.
Risk-proportionate regulation is the organising idea. A trial's regulatory burden is meant to track the risk it presents to participants, so that the lower-risk work that occupies much of the research pipeline is not processed at the intensity designed for first-in-human studies.
One requirement is entirely new rather than a change to an existing route. The regulations legally require, for the first time, that trials be registered on a World Health Organization-recognised public register and that results summaries be published. Earlier registration and reporting practice depended on funder and journal conditions rather than statute.
The intended outcomes are stated as a list rather than a single measure. The MHRA describes the reforms as cutting duplication and delays while maintaining oversight, creating a flexible environment for lower-risk trials, and positioning the UK as a destination for international trials. Each of those is a separate claim requiring its own evidence.
The implementation period is doing work of its own. The Health Research Authority is publishing guidance to support sponsors, researchers and trial teams preparing for the changes, and offering opportunities to shape how the new transparency requirements are introduced before they take full effect.
Combined Review already existed as a route before it was written into law. What the regulations change is its status: the HRA describes embedding it in statute as the mechanism that gives the process a firmer footing, alongside a strengthened focus on transparency and proportionality. A process that regulators operate by agreement is one they can vary. One written into law is not, at least not without amending it again.
The approval timetable
The MHRA has stated that the framework supports the Prime Minister's target of reducing the time from application to first participant from 250 days to 150 days.
That is a target, and the distinction matters. A target describes an intended performance level for the system as a whole. It is not a measurement of what the system does, and no published outcome against the 250-day baseline was located in the sources reviewed for this article.
The baseline itself has a history that complicates any comparison. The list of authorised trials and the intervals between application and decision are recorded in MHRA performance data for the assessment of clinical trials and established medicines, published separately as operational figures. Reading whether the target is being met requires those figures and a period long enough to reflect the new process rather than the old one.
The target also concerns one interval within the pathway, not the pathway. Time from application to first participant covers the regulatory and ethics stages that the MHRA and HRA control. It excludes site selection, contracts, recruitment of participants and clinical readiness, all of which sit outside the regulator and some of which take longer than the approval itself. A regulator that meets its own target has improved one component of a process it only partly governs.
What is not yet known
The regulations took full effect on 28 April 2026. Any assessment of whether they shortened approval times is therefore measuring a system that has been operating under the new rules for months, not years, and the trials now in the queue were designed and submitted under the previous framework.
What is not yet known is whether the 150-day target is met in practice. The sources reviewed here contain the target and the mechanisms intended to serve it; they do not contain post-commencement performance data showing the interval actually achieved. Whether Combined Review and the notification scheme reduce the time to first participant, and by how much, is not yet known. It will be answerable from MHRA performance data once a full reporting period under the new framework is complete.
Summary
The UK has replaced its clinical trials regulations, embedded Combined Review and notification in law, and set a 250-to-150-day target for the interval from application to first participant. The target is not yet a measurement.
- The framework is in force. The 2025 amending regulations took full effect on 28 April 2026, after an eighteen-day delay for re-signing.
- Two mechanisms are statutory. Combined Review and the notification scheme for certain lower-risk applications are written into law.
- The organising principle is proportionality. Regulatory burden is intended to track the risk a trial presents to its participants.
- The headline number is a target. Reducing application-to-first-participant time from 250 to 150 days is a government aim, not a reported outcome.
- The evidence for effectiveness is pending. No post-commencement performance figures for the new framework were located in the sources reviewed.
Whether the 150-day target is being met is not yet known.
Research direction and editorial oversight: Juno Uni Hera. AI-assisted research and drafting; human review is ongoing.
Sources
- The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025. legislation.gov.uk, SI 2025/538. https://www.legislation.gov.uk/uksi/2025/538/contents/made
- Medicines and Healthcare products Regulatory Agency. Clinical Trials regulations signed into law. GOV.UK (2025). https://www.gov.uk/government/news/clinical-trials-regulations-signed-into-law
- Health Research Authority. Combined review. HRA. https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/clinical-trials-investigational-medicinal-products-ctimps/combined-review
- Health Research Authority. New UK clinical trials regulations signed into law: implementation period begins. HRA. https://www.hra.nhs.uk/about-us/news-updates/new-uk-clinical-trials-regulations-signed-into-law-implementation-period-begins
- Medicines and Healthcare products Regulatory Agency. MHRA performance data for assessment of clinical trials and established medicines. GOV.UK. https://www.gov.uk/government/publications/mhra-performance-data-for-assessment-of-clinical-trials-and-established-medicines/mhra-performance-data-for-assessment-of-clinical-trials-and-established-medicines--2